One Georgia couple has some hope after a possible breakthrough in an Alzheimer's drug that can reduce thinking declines by about 27%.
NBC News medical contributor Dr. Kavita Patel joins News NOW to explain how a new Alzheimer’s drug could signal a potential breakthrough in treatment for the disease.
- Yahoo Finance Video
Yahoo Finance's Anjalee Khemlani discusses positive news around an Alzheimer's drug, plus reports that China is considering a fourth round of COVID vaccines.
- Yahoo Canada Style
"You are what you eat" isn't just an old adage — it's the truth when it comes to your brain.
- Eating Well
Lower rates of cognitive decline were found in people who included more of these foods in their diet.
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.
Juliette Goodrich reports on how a new study indicates changes in lifestyle can reduce risks of Alzheimer's and dementia (11-30-2022)
The New England Journal of Medicine found that "longer trials are warranted to determine the efficacy and safety" of lecanemab
- CBS News Videos
Actor Chris Hemsworth revealed he is taking a break from acting after discovering he carries two copies of a gene associated with high risk of developing Alzheimer's disease. Dr. Dona Kim Murphey, a neurologist and co-founder of Prognosus, joins CBS News' Lana Zak to discuss ways to lower your risk of developing the disease, and the potential impact of an experimental drug that may lower the rate of cognitive decline.
- Associated Press
Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better treatments of the incurable disease. The data was presented at an Alzheimer’s meeting in San Francisco and published in The New England Journal of Medicine. Lecanemab delayed patients’ worsening by about five months over the course of the 18-month study, Eisai’s Dr. Michael Irizarry told The Associated Press.
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.
Neurologist Dr. Paul Schultz with UTHealth Houston and Memorial Hermann talks about the Alzheimer's drug and what it means for the treatment of Alzheimer's.
- The Telegraph
Scientists treating Alzheimer's have made a 'game-changing' leap forward in treatment for the disease, with a drug that could spell 'the beginning of the end' of the condition.
- The Wall Street Journal
The drug from Eisai and Biogen slowed cognitive decline in study volunteers, but many had brain bleeds, swelling or other side effects.
Researchers report on a critical step toward an effective treatment for the neurodegenerative disease.
- The Independent
One in four sufferers commonly go two years undiagnosed, one study claims
Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost.
Swiss drugmaker Roche is closing down most clinical trials of its experimental Alzheimer's drug gantenerumab after it failed to slow advance of the mind-robbing disease in a pair of large, late-stage studies, the company said on Wednesday. Roche presented full results of twin trials at an Alzheimer's meeting in San Francisco after announcing in November that the drug had failed in the two trials. Unlike Eisai Co Ltd and Biogen Inc's lecanemab, which appears to be on track for U.S. regulatory approval after presenting successful trial results on Tuesday, Roche's drug did not show a statistically significant benefit in patients with mild cognitive impairment and early Alzheimer's disease.
Shares in pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of the lecanemab drug.
New phase 3 clinical trial data for lecanemab, an experimental drug to fight Alzheimer’s disease, shows promise.
A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed
A new study found that Eisai and Biogen's experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half.